AWM Investment Company Inc. Has $4.02 Million Stake in Progyny, Inc. $PGNY

Key Points

• AWM Investment Company Inc. increased its stake in Progyny by 12.5%, now holding 180,000 shares worth approximately $4.02 million.
• Progyny's stock recently decreased by 1.1%, trading at $23.41, with a market cap of $2.01 billion and a P/E ratio of 39.68.
• Despite missing earnings expectations, Progyny reported a revenue increase of 9.5% year-over-year and has received upgrades from various analysts, setting target prices up to $28.00.

AWM Investment Company Inc. increased its position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 12.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 180,000 shares of the company's stock after purchasing an additional 20,000 shares during the period. AWM Investment Company Inc. owned approximately 0.21% of Progyny worth $4,021,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Progyny in the 1st quarter valued at about $44,000. Brooklyn Investment Group grew its position in shares of Progyny by 5,216.4% in the 1st quarter. Brooklyn Investment Group now owns 3,243 shares of the company's stock worth $72,000 after buying an additional 3,182 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Progyny by 233.9% in the 1st quarter. GAMMA Investing LLC now owns 5,379 shares of the company's stock worth $120,000 after buying an additional 3,768 shares during the last quarter. AlphaQuest LLC grew its position in shares of Progyny by 57.9% in the 1st quarter. AlphaQuest LLC now owns 5,668 shares of the company's stock worth $127,000 after buying an additional 2,079 shares during the last quarter. Finally, State of Wyoming grew its position in shares of Progyny by 98.2% in the 4th quarter. State of Wyoming now owns 12,376 shares of the company's stock worth $213,000 after buying an additional 6,132 shares during the last quarter. 94.93% of the stock is owned by hedge funds and other institutional investors.

Progyny Stock Up 1.1%

PGNY stock traded up $0.26 during mid-day trading on Monday, hitting $22.81. 323,884 shares of the company were exchanged, compared to its average volume of 1,380,391. The firm has a market capitalization of $1.96 billion, a P/E ratio of 38.61, a PEG ratio of 1.84 and a beta of 1.33. The business has a fifty day simple moving average of $22.94 and a 200-day simple moving average of $22.22. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $26.76.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.42 by ($0.23). The business had revenue of $332.87 million for the quarter, compared to analysts' expectations of $315.70 million. Progyny had a return on equity of 10.69% and a net margin of 4.28%.The business's revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the business posted $0.17 earnings per share. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. Research analysts predict that Progyny, Inc. will post 0.6 EPS for the current year.

Insider Buying and Selling at Progyny

In other news, EVP Allison Swartz sold 2,398 shares of the company's stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $22.96, for a total transaction of $55,058.08. Following the completion of the transaction, the executive vice president owned 79,697 shares in the company, valued at approximately $1,829,843.12. This represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Cheryl Scott sold 2,675 shares of the firm's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $22.07, for a total transaction of $59,037.25. Following the transaction, the director directly owned 14,112 shares in the company, valued at approximately $311,451.84. The trade was a 15.93% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,570 shares of company stock valued at $238,348 in the last three months. Corporate insiders own 9.40% of the company's stock.

Wall Street Analysts Forecast Growth

PGNY has been the topic of several recent research reports. Canaccord Genuity Group upped their price objective on shares of Progyny from $21.00 to $23.00 and gave the company a "hold" rating in a report on Wednesday, August 20th. Leerink Partnrs upgraded shares of Progyny from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 8th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $28.00 target price (up from $26.00) on shares of Progyny in a research note on Friday, August 8th. JPMorgan Chase & Co. boosted their target price on shares of Progyny from $23.00 to $25.00 and gave the company a "neutral" rating in a research note on Tuesday, August 26th. Finally, Wall Street Zen upgraded shares of Progyny from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Progyny has an average rating of "Moderate Buy" and an average price target of $25.30.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.